BlackRock Investment Management’s Zevra Therapeutics ZVRA Stock Holding History

BlackRock Investment Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$6K	Hold	128	–	–	﹤0.01%	3740
2016 Q3	$9K	Hold	128	–	–	﹤0.01%	3641
2016 Q2	$8K	Buy	128 +66	+106%	+$10.9K	﹤0.01%	3725
2016 Q1	$14K	Hold	62	–	–	﹤0.01%	3492
2015 Q4	$20K	Buy	62 +4	+7%	+$1.09K	﹤0.01%	3434
2015 Q3	$18K	Hold	58	–	–	﹤0.01%	3472
2015 Q2	$17K	Buy	+58	New	+$12.6K	﹤0.01%	3504

Other funds holding ZVRA

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock Investment Management's ZVRA Position: Q4 2016 in Review

BlackRock Investment Management held its Zevra Therapeutics (ZVRA) position steady in Q4 2016 at 128 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #3740.

BlackRock Investment Management first reported a position in ZVRA in Q2 2015 and has held it in 7 quarters since. The position peaked at $20K in Q4 2015. 36 funds tracked by Wall St. Rank hold ZVRA as of Q4 2016.

BlackRock Investment Management held 128 shares of Zevra Therapeutics worth $6K as of Q4 2016.
BlackRock Investment Management left its Zevra Therapeutics share count unchanged in Q4 2016.
Zevra Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3740 holding.
BlackRock Investment Management first reported a position in Zevra Therapeutics in Q2 2015 and has held it in 7 quarters since.
BlackRock Investment Management's Zevra Therapeutics position peaked at $20K in Q4 2015.
36 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.